Stock Ticker

  • Loading stock data...

Merck & Co Inc. (NYSE:MRK) Bolstering Its Oncology Pipeline With Acquisition Of VelosBio

Merck & Co Inc. (NYSE:MRK) has entered a definitive agreement for the acquisition of all outstanding shares of Pappas Capital’s portfolio firm VelosBio via a subsidiary to consider $2.75 billion. However, the closing of the deal is subject to approval under the Hart-Scott-Rodino improvement and customary adjustments. VelosBio developing oncology therapies targeting ROR1 VelosBio is […]